fda update on semaglutide Novo Nordisk has announced that the has approved the Wegovy® pill (once-daily oral 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults FDA Updates Semaglutide Product Specific

The most commonly reported side effects are nausea, vomiting, loss of appetite, and abdominal pain, though some people experience other less common side effects, including vision changes and eye problems

This includes a decrease in enrollment for large firms (from 83% in 2023 to 79% in 2024) and a slight increase in small firms (from 18% to 20%)

Guidelines and Considerations Semaglutide is generally safe for adults who meet eligibility criteria

It may simply mean that your provider needs to: Adjust your dose Combine treatment with another supportive modality (like BioBoost) Investigate root causes (thyroid dysfunction, insulin resistance, etc.) Support lifestyle or mental health factors that could be interfering with success

Singh P, Pesavento TE, Washburn K, Walsh D, Meng S

**Improved Joint Function** Beyond pain relief, BPC-157 has been associated with improved joint function